The spread of SARS-CoV-2 has been accompanied by troubling disparities in infections, hospitalizations, and deaths. This issue brief underscores lessons from the HIV/AIDS epidemic, outlining the need for comprehensive data to design and carry out appropriate mitigation measures. It draws comparisons to the HIV epidemic and identifies gaps in race/ethnicity data in routine COVID-19 case reporting and explores risk factors for exposure that may be driving disparities in COVID-19 outcomes.
This issue brief is intended to help health care providers and patients better understand how the U.S. Preventive Services Task Force (USPSTF) Grade A recommendation for pre-exposure prophylaxis (PrEP) and Senate Bill (SB) 159 will impact PrEP access in California
(Updated 3/10/2021)On March 9, 2021, the U.S. Department of Justice decided to stop defending the Trump-era public charge regulations. The U.S. Supreme Court dismissed the pending appeals. This means that the lower court decision to vacate the public charge rule is now in effect. This means that the 2019 Final Public Charge rule is permanently blocked, nationwide. This notice will be revised as further updates develop.To limit any confusion related to the Final Public Charge rule and its effects, community resources related to the now blocked regulations will be archived. They are available upon request.
(Actualizado el 10 de Marzo del 2021)El 9 de Marzo del 2021, el Departamento de Justicia de EE. UU. decidió dejar de defender las regulaciones de carga pública de la era Trump. La Corte Suprema de Estados Unidos desestimó las apelaciones pendientes. Esto significa que la decisión del tribunal inferior de anular la regla de carga pública ya está en vigor. También significa que la regla de Carga Pública Final del 2019 está bloqueada permanentemente en todo el país. Este aviso será revisado a medida que se desarrollen más actualizaciones.Para limitar cualquier confusión relacionada con la regla de Carga Pública ... [Read More];
Contingency management (CM) is a behavioral intervention that promotes healthy behavior using positive reinforcement in the form of rewards. Originally developed to treat substance use disorders, CM was adopted by public health practitioners and policymakers to help bring about a variety of positive health outcomes, including employment seeking behaviors, starting and continuing to take prescribed medications for the prevention of HIV, and remaining engaged in HIV care. This brief describes CM, key concerns, efficacy for use with people living with HIV, and people who use substances.
Send this to a friend